These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9061568)

  • 1. Decreased platelet membrane anisotropy in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.
    Stöckler S; Opper C; Greinacher A; Hunneman DH; Korenke GC; Unkrig CJ; Hanefeld F
    J Inherit Metab Dis; 1997 Mar; 20(1):54-8. PubMed ID: 9061568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of erucic acid on platelets in patients with adrenoleukodystrophy.
    Kickler TS; Zinkham WH; Moser A; Shankroff J; Borel J; Moser H
    Biochem Mol Med; 1996 Apr; 57(2):125-33. PubMed ID: 8733890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced lymphocyte proliferation in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.
    Pour RB; Stöckler-Ipsiroglu S; Hunneman DH; Gahr M; Korenke GC; Pabst W; Hanefeld F; Peters A
    J Inherit Metab Dis; 2000 Mar; 23(2):113-9. PubMed ID: 10801052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant platelets in erucic acid therapy for adrenoleukodystrophy.
    Stöckler S; Molzer B; Plecko B; Zenz W; Muntean W; Söling U; Hunneman DH; Korenke C; Hanefeld F
    Lancet; 1993 May; 341(8857):1414-5. PubMed ID: 8098819
    [No Abstract]   [Full Text] [Related]  

  • 5. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
    van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding in a patient taking Lorenzo's oil: evidence for a vascular defect.
    Chai BC; Etches WS; Stewart MW; Siminoski K
    Postgrad Med J; 1996 Feb; 72(844):113-4. PubMed ID: 8871463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorenzo's oil and platelet activation in adrenomyeloneuropathy and asymptomatic X-linked adrenoleukodystrophy.
    Konijnenberg A; van Geel BM; Sturk A; Schaap MC; von dem Borne AE; de Bruijne-Admiraal LG; Schutgens RB; Assies J; Barth PG
    Platelets; 1998; 9(1):41-8. PubMed ID: 16793744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorenzo's oil.
    Moser HW
    Lancet; 1993 Feb; 341(8844):544. PubMed ID: 8094785
    [No Abstract]   [Full Text] [Related]  

  • 9. The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzo's oil.
    Suzuki Y; Imamura A; Shimozawa N; Kondo N
    Brain Dev; 2001 Mar; 23(1):30-3. PubMed ID: 11226726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.
    Poulos A; Gibson R; Sharp P; Beckman K; Grattan-Smith P
    Ann Neurol; 1994 Nov; 36(5):741-6. PubMed ID: 7979219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
    Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
    J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy.
    Duchesne N; Dufour M; Bouchard G; Grondin P; Lemieux B
    Can Assoc Radiol J; 1995 Oct; 46(5):386-91. PubMed ID: 7552831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
    Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
    Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Lorenzo's Oil on peroxisomes in healthy mice.
    De Craemer D; Van den Branden C; Fontaine M; Vamecq J
    Prostaglandins Other Lipid Mediat; 1998 Mar; 55(4):237-44. PubMed ID: 9644114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).
    Rasmussen M; Moser AB; Borel J; Khangoora S; Moser HW
    Neurochem Res; 1994 Aug; 19(8):1073-82. PubMed ID: 7800117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia associated with use of Lorenzo's oil.
    Chai BC; Siminoski K
    Am J Hematol; 1993 Dec; 44(4):290-1. PubMed ID: 8238006
    [No Abstract]   [Full Text] [Related]  

  • 17. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.
    Moser HW; Raymond GV; Lu SE; Muenz LR; Moser AB; Xu J; Jones RO; Loes DJ; Melhem ER; Dubey P; Bezman L; Brereton NH; Odone A
    Arch Neurol; 2005 Jul; 62(7):1073-80. PubMed ID: 16009761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorenzo's oil therapy of adrenoleukodystrophy.
    DiGregorio VY; Schroeder DJ
    Ann Pharmacother; 1995 Mar; 29(3):312-3. PubMed ID: 7606079
    [No Abstract]   [Full Text] [Related]  

  • 19. Lorenzo's oil may help to prevent ALD symptoms.
    Senior K
    Lancet Neurol; 2002 Dec; 1(8):468. PubMed ID: 12849323
    [No Abstract]   [Full Text] [Related]  

  • 20. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.
    Aubourg P; Adamsbaum C; Lavallard-Rousseau MC; Rocchiccioli F; Cartier N; Jambaqué I; Jakobezak C; Lemaitre A; Boureau F; Wolf C
    N Engl J Med; 1993 Sep; 329(11):745-52. PubMed ID: 8350883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.